ALX Oncology's Breakthrough in Treating Indolent Non-Hodgkin Lymphoma
ALX Oncology Holdings Inc. (NASDAQ: ALXO), a pioneer in biotechnology, has recently announced remarkable results from its Phase 2 investigator-sponsored trial evaluating evorpacept in combination with standard treatments for indolent B-cell non-Hodgkin lymphoma. The trial is generating excitement among healthcare professionals and patients alike, showcasing the potential for significant advancements in cancer treatment.
Impressive Results from the Phase 2 Trial
The combination of evorpacept, rituximab, and lenalidomide—referred to as R2—achieved a striking complete response rate of 92% among patients. This notably exceeds the historical complete response rate of approximately 50% for R2 alone. This result not only highlights the efficacy of the new regimen but also establishes a promising benchmark for further treatments in the future.
Effectiveness and Patient Tolerance
Data revealed that the combination therapy was well-tolerated among the participants, providing impressive anti-tumor activity, particularly for patients in the frontline treatment setting. As the study matures, the researchers plan to assess the rate of minimal residual disease (MRD) eradication, offering further insights into the long-term effectiveness of this innovative regimen.
Clinical Trial Overview and Objectives
Conducted by Dr. Paolo Strati at The University of Texas MD Anderson Cancer Center, this clinical trial aimed to involve patients with previously untreated indolent non-Hodgkin lymphoma. A total of 24 patients participated, including 14 with follicular lymphoma and 10 with marginal zone lymphoma. The trial successfully met its primary objective of achieving a best complete response rate exceeding 80%.
Key Findings from the Study
The results are compelling; 92% of patients reached a complete response, while the overall response rate stood at an impressive 100%. Additionally, the figures indicate a one-year progression-free survival (PFS) rate of 91% and a one-year overall survival (OS) rate of 100%. This establishes the new therapy not just as a viable option but as a critical element in combating this form of cancer.
Details of the Presentation at ASH Annual Meeting
ALX Oncology's findings will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting. Details of the poster presentation are as follows:
Title: A phase II investigator-initiated frontline trial of evorpacept (ALX148), lenalidomide, and rituximab for high tumor burden indolent B-cell non-Hodgkin lymphoma
Presenter: Paolo Strati, M.D., Associate Professor
Presentation ID: 3571
Date/Time: December 7, 2025; 8:00 a.m. - 8:00 p.m. EST
Session Type: Poster Session
About ALX Oncology and Its Vision
ALX Oncology is dedicated to advancing the field of immuno-oncology, focusing on developing novel therapies that aim to enhance patient outcomes. Evorpacept is one of the key candidates in their pipeline, currently being assessed across several clinical trials for various cancer types. Along with evorpacept, ALX Oncology is also investigating its second pipeline candidate, ALX2004, which is designed to target the EGFR and has made promising strides in clinical testing.
Future Directions for ALX Oncology
With ongoing trials and advancements in therapeutic strategies, ALX Oncology is well-positioned to contribute significantly to improving cancer care. The focus remains on innovative solutions that extend and enhance the quality of life for cancer patients, marking a hopeful future in oncology.
Frequently Asked Questions
What is evorpacept?
Evorpacept is a novel therapeutic candidate being researched by ALX Oncology, aimed at treating various types of cancer, including indolent non-Hodgkin lymphoma.
What were the results of the Phase 2 trial?
The trial reported a complete response rate of 92% among patients treated with the combination of evorpacept and standard therapies.
Who conducted the trial?
The clinical trial was led by Dr. Paolo Strati from The University of Texas MD Anderson Cancer Center.
What is the significance of the ASH Annual Meeting presentation?
This presentation will share critical data about evorpacept's efficacy, potentially leading to broader recognition and future clinical use.
How is ALX Oncology contributing to cancer research?
ALX Oncology is committed to developing innovative therapies for cancer treatment, focusing on improving patient outcomes and expanding therapeutic options.
